These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35988810)

  • 1. Genotoxicity evaluation of a valsartan-related complex N-nitroso-impurity.
    Glowienke S; Onken U; Elhajouji A; Muthusamy S; Sangana R; Martus HJ; Bedman T; Hartmann A
    Regul Toxicol Pharmacol; 2022 Oct; 134():105245. PubMed ID: 35988810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ames test study designs for nitrosamine mutagenicity testing: qualitative and quantitative analysis of key assay parameters.
    Thomas DN; Wills JW; Tracey H; Baldwin SJ; Burman M; Williams AN; Harte DSG; Buckley RA; Lynch AM
    Mutagenesis; 2024 Mar; 39(2):78-95. PubMed ID: 38112628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
    Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
    Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
    Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
    Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A deep dive into historical Ames study data for N-nitrosamine compounds.
    Tennant RE; Ponting DJ; Thresher A
    Regul Toxicol Pharmacol; 2023 Sep; 143():105460. PubMed ID: 37495012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data.
    Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R
    Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities.
    Charoo NA; Ali AA; Buha SK; Rahman Z
    AAPS PharmSciTech; 2019 Apr; 20(5):166. PubMed ID: 30989447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Quantitation of Four Nitrosamine Impurities in Angiotensin Receptor Blocker Drug Substances.
    Zhang J; Selaya SD; Shakleya D; Mohammad A; Faustino PJ
    J Pharm Sci; 2023 May; 112(5):1246-1254. PubMed ID: 36509171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potential.
    Cheung J; Dobo K; Zhang S; Nudelman R; Schmidt F; Wenzel J; Czich A; Schuler M
    Environ Mol Mutagen; 2024 Jul; 65(6-7):203-221. PubMed ID: 39180320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified NAP test: A simple and Responsive Nitrosating Methodology for Risk Evaluation of NDSRIs.
    Sharma N; Patel R; Bothara T; Jain S; Shah RP
    J Pharm Sci; 2023 May; 112(5):1333-1340. PubMed ID: 36871894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control.
    Tuesuwan B; Vongsutilers V
    J Pharm Sci; 2021 Sep; 110(9):3118-3128. PubMed ID: 33989680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s.
    Li X; He X; Le Y; Guo X; Bryant MS; Atrakchi AH; McGovern TJ; Davis-Bruno KL; Keire DA; Heflich RH; Mei N
    Arch Toxicol; 2022 Nov; 96(11):3077-3089. PubMed ID: 35882637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous and trace level quantification of two potential genotoxic impurities in valsartan drug substance using UPLC-MS/MS.
    Li S; Dong L; Tang K; Lan Z; Liu R; Wang Y; Wang R; Lin H
    J Pharm Biomed Anal; 2022 Apr; 212():114630. PubMed ID: 35158183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of acceptable daily intake values based on modeling and in vivo mutagenicity of NDSRIs of fluoxetine, duloxetine and atomoxetine.
    Jolly RA; Cornwell PD; Noteboom J; Sayyed FB; Thapa B; Buckley LA
    Regul Toxicol Pharmacol; 2024 Sep; 152():105672. PubMed ID: 38968965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
    Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
    J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of less-than-lifetime (LTL) durational limits for nitrosamines: Case study of N-Nitrosodiethylamine (NDEA).
    Bercu JP; Masuda-Herrera M; Johnson G; Czich A; Glowienke S; Kenyon M; Thomas R; Ponting DJ; White A; Cross K; Waechter F; Rodrigues MAC
    Regul Toxicol Pharmacol; 2021 Jul; 123():104926. PubMed ID: 33862169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotoxicity assessment of eight nitrosamines using 2D and 3D HepaRG cell models.
    Seo JE; Yu JZ; Xu H; Li X; Atrakchi AH; McGovern TJ; Bruno KLD; Mei N; Heflich RH; Guo X
    Arch Toxicol; 2023 Oct; 97(10):2785-2798. PubMed ID: 37486449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of false positive, contaminant-driven mutagenicity in impurities associated with the sotorasib drug substance.
    Coppi A; Davies R; Wegesser T; Ishida K; Karmel J; Han J; Aiello F; Xie Y; Corbett MT; Parsons AT; Monticello TM; Minocherhomji S
    Regul Toxicol Pharmacol; 2022 Jun; 131():105162. PubMed ID: 35331777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines.
    Snodin DJ
    Regul Toxicol Pharmacol; 2023 Jun; 141():105403. PubMed ID: 37116739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revisiting the Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.
    Burns MJ; Ponting DJ; Foster RS; Thornton BP; Romero NE; Smith GF; Ashworth IW; Teasdale A; Simon S; Schlingemann J
    J Pharm Sci; 2023 Dec; 112(12):3005-3011. PubMed ID: 37805074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.